Delivering on our promises
We have taken significant strides to expand our operating space through the acquisitions of Abide and Alder in 2019, which gave us the platforms needed to expand our areas of focus in neuroscience. With the 2020 launch of our newest treatment, for migraine, in the U.S. and the global roll-out which was initiated in 2021, we are beginning to establish a new frontier in migraine prevention and expanding our presence into protein-based therapies. Furthermore, we are continuously expanding our existing portfolio of medicine into new markets.
The changes we made to how we approach R&D enables us to de-risk our internal pipeline compounds in early development. We utilize an experimental medicine approach to identify the effects of a drug in carefully selected patient populations, to find the most efficient clinical pathway powered by biomarkers and study designs and advance the most promising drug candidates into full development.
We have made choices on where to accelerate and enhance the use of digital within our operations and R&D. Also, we have taken steps to fortify our winning culture with increased agility, collaboration, diversity and inclusion. These are just a few of the many actions that are helping us deliver on the promise of our strategy to yield sustainable, long-term profitable growth.
We are well on our way with the strategic reorientation of our business to discover and develop transformative medications for indications in niche neurology and psychiatry treated by specialists, and rare diseases in neurology, so we can best deliver to patients and maintain a leadership position among Europe based pharmaceutical companies of our size and scope. As we continue to forge ahead with our Expand and Invest to Grow strategy, we are pleased with our progress. deborah dunsire, president & CEO
Our goal continues to be providing innovative treatments for patients that create value for Lundbeck. Achieving our fullest potential as a mid-size, highly specialized pharmaceutical company requires that we thoughtfully concentrate our efforts where we can make the most difference for patients.
While we maximize the medicines and brands that we already have, we simultaneously focus on growing our pipeline with treatments for brain diseases for which there are few, if any, treatment options. We operate within niche diseases affecting subpopulations of people where there is a high, unmet medical need. By focusing on niche and rare disease neurology and psychiatry indications, we can best take advantage of our size and strong relationships with specialist healthcare providers to deliver powerful solutions to challenging diseases.
Just as important to growing our pipeline and selling our medicines, is the manufacturing of our medicines, whether internally or via external contract manufacturing. We have strong internal capabilities within small and large molecules to support our R&D pipeline, including monoclonal antibody design, process and formulation development capabilities, as well as end-to-end internal small molecule manufacturing facilities.
Our three priorities across Production, Development & Supply remain quality, reliability and cost. We have a robust track-record on all three parameters and ambitious goals to continuously improve performance with a strong focus on operational excellence and sustainable sourcing.
We aim to build on what we have achieved and capitalize further on the strong fundamentals that are deeply ingrained in Lundbeck; our rich heritage of developing and producing life-changing treatments for patients, our deep scientific knowledge in psychiatry and neurology and our patient-centric mindset. We will focus on embracing new biologies and technologies, adjusting and learning as we forge ahead.
In the future, we will work with even more agility and collaboration across geographies, simplifying our processes and accelerating our ability to test and learn for faster, higher-quality decision making. This will fully leverage our diverse talent, knowledge and skillsets so that we can pursue solving some of the biggest brain disease challenges with the greatest patient reward.
There are five strategic imperatives at the core of Lundbeck’s strategy.
“We have made great progress against the strategic imperatives, expanding our operating space and rebuilding our pipeline to drive future growth”. Deborah Dunsire, President & CEO
Over the past two years, we have made strategic choices around where we put our efforts across our entire business. With the choices we made, we have lofty ambitions for what the future should look like when we succeed.
We aim to be the leader in brain health, in the eyes of our patients. We know we are well on our way when:
The culmination of all this together is what will make us #1 in Brain Health, serving the people who need new medicines to help them conquer brain diseases. It will take every brain being fully “in the game” to achieve it. We continue to prioritize and act, year by year to stay on track.
Discover our projects and compounds in development.
Lundbeck has developed some of the world’s most widely prescribed therapies.
Lundbeck remains committed to sustainability through our strong strategy.